This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Beta blockers and hyperlipidaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • tend to result in an increase in triglyceride level (via an increase in VLDL) and a reduction in HDL
    • increase in VLDL appears to be result of reduced clearance of triglyceride-rich lipoproteins (possibly via direct effect on lipoprotein lipase or perhaps because of diversion of blood flow from sites rich in lipoprotein lipase e.g. muscle vascular bed)
  • do not appear to affect total cholesterol or LDL cholesterol
  • if a patient has a predisposition to hypertriglyceridaemia then beta blocker effect can be marked

Labetalol, which posseses both alpha and beta-blocking activity, is reported to have little effect on serum lipids. Also beta-blockers with intrinsic sympathomimetic activity e.g. acebutolol and oxprenolol, are reported to have little effect on serum lipids.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.